KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBITDA Margin (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EBITDA Margin for 13 consecutive years, with 354.42% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 44462.0% to 354.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 237.62% through Dec 2025, up 89079.0% year-over-year, with the annual reading at 237.62% for FY2025, 89079.0% up from the prior year.
  • EBITDA Margin hit 354.42% in Q4 2025 for Arbutus Biopharma, up from 1452.55% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 23.3% in Q2 2025 to a low of 1456.24% in Q3 2024.
  • Historically, EBITDA Margin has averaged 668.79% across 5 years, with a median of 622.09% in 2021.
  • Biggest five-year swings in EBITDA Margin: plummeted -103717bps in 2024 and later skyrocketed 116658bps in 2025.
  • Year by year, EBITDA Margin stood at 669.65% in 2021, then skyrocketed by 49bps to 342.93% in 2022, then tumbled by -156bps to 878.74% in 2023, then rose by 9bps to 799.05% in 2024, then soared by 56bps to 354.42% in 2025.
  • Business Quant data shows EBITDA Margin for ABUS at 354.42% in Q4 2025, 1452.55% in Q3 2025, and 23.3% in Q2 2025.